TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02422901

Intervention type: DRUG
Intervention: vitamin C
Description: According to the character of an observational study no intervention other than the administration of Pascorbin® 7.5g (which is administered routinely in these cases) is provided.

Intervention type: DRUG
Intervention: vitamin C
Description: According to the character of an observational study no intervention other than the administration of Pascorbin® 7.5g (which is administered routinely in these cases) is provided.
Study: NCT00230763

Intervention type: PROCEDURE
Group type: OTHER
Intervention: GSS questionnaire
Description: D0, D30 and D84
Study: NCT01019551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART Intensification
Description: Current ART regimen plus raltegravir and maraviroc Raltegravir : 400 mg PO BID for 56 weeks Maraviroc : 150, 300 or 600 mg PO BID depending on concomitant ART treatment, for 56 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART Intensification
Description: Current ART regimen plus raltegravir and maraviroc Raltegravir : 400 mg PO BID for 56 weeks Maraviroc : 150, 300 or 600 mg PO BID depending on concomitant ART treatment, for 56 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunomodulation
Description: Starting at Week 8, 1 cycle of 3 injections (1 per week) of recombinant human Interleukin-7 (r-hIL-7 / CYT107) at a 20 µg/kg dose.
Study: NCT02455180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Patients receive vitamin C 4 times in either high (5g) or moderate (1g) dose. Vitamin C will be administered intravenously (ascorbinezuur CF 100 mg/ml, Centrafarm BV, Etten Leur, Netherlands) in 50ml of NaCl 0.9%, infused over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Patients receive vitamin C 4 times in either high (5g) or moderate (1g) dose. Vitamin C will be administered intravenously (ascorbinezuur CF 100 mg/ml, Centrafarm BV, Etten Leur, Netherlands) in 50ml of NaCl 0.9%, infused over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Patients receive vitamin C 4 times in either high (5g) or moderate (1g) dose. Vitamin C will be administered intravenously (ascorbinezuur CF 100 mg/ml, Centrafarm BV, Etten Leur, Netherlands) in 50ml of NaCl 0.9%, infused over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Patients receive vitamin C 4 times in either high (5g) or moderate (1g) dose. Vitamin C will be administered intravenously (ascorbinezuur CF 100 mg/ml, Centrafarm BV, Etten Leur, Netherlands) in 50ml of NaCl 0.9%, infused over 30 minutes.
Study: NCT04779723

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of two Techniques of bariatric surgery
Description: We compared the 30 days outcomes in patients who underwent LSG procedure with those who underwent LRYGB

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of two Techniques of bariatric surgery
Description: We compared the 30 days outcomes in patients who underwent LSG procedure with those who underwent LRYGB
Study: NCT02301091

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: TACE will be done according to the current method in our center. We use intra-injection of lipiodol mixed with pirarubicin,mitomycin and lobaplatin when the catheter was placed in the superselective location very close to the tumor. Gelfoam sponge was then injected to temporarily occlude the arterial blood flow.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE will be done according to the current method in our center. We use intra-injection of lipiodol mixed with pirarubicin,mitomycin and lobaplatin when the catheter was placed in the superselective location very close to the tumor. Gelfoam sponge was then injected to temporarily occlude the arterial blood flow.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA
Description: For RFA, we used two commercially available system (Cool-Tip, Valleylab，USA) and (Octopus RF Systema，Starmed,Korea）with needle electrode with a 17-gauge internally cooled electrode.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pirarubicin,mitomycin and lobaplatin
Description: They were cytotoxic drugs used in the TACE procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pirarubicin,mitomycin and lobaplatin
Description: They were cytotoxic drugs used in the TACE procedure.
Study: NCT02855983

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat Grafting
Description: Grafting of autologous fat tissue is a minimally invasive surgical technique that starts with the harvest of fat tissue from the abdomen or thighs using liposuction through incisions less than 2mm in length. The lipoaspirate is then processed to concentrate the adipose fraction and reinjected into the graft site. This surgical procedure involves the immediate transplantation of a patient's own tissue in a single operative procedure.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fat Grafting
Description: Grafting of autologous fat tissue is a minimally invasive surgical technique that starts with the harvest of fat tissue from the abdomen or thighs using liposuction through incisions less than 2mm in length. The lipoaspirate is then processed to concentrate the adipose fraction and reinjected into the graft site. This surgical procedure involves the immediate transplantation of a patient's own tissue in a single operative procedure.
Study: NCT00120874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized management of AD including caregiver training
Description: Individualized management program: consists of home visits to get the patient exercising, doing enjoyable activities and cognitive stimulation, educational sessions for caregivers on coping with difficult situations and a caregiver support group to help with questions and emotional concerns.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Patients receive 10 milligrams of memantine twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Patients receive 10 milligrams of memantine twice daily.
Study: NCT03406975

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Overstitch Endoscopic Suture System
Description: Endoscopic Sleeve Gastroplasty (ESG), an endoscopic minimally-invasive weight loss procedure, utilizing a suturing device to reduce the stomach volume by 80% through the creation of sleeve. This is accomplished by a series of endoscopically placed stitches through the stomach wall.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Overstitch Endoscopic Suture System
Description: Endoscopic Sleeve Gastroplasty (ESG), an endoscopic minimally-invasive weight loss procedure, utilizing a suturing device to reduce the stomach volume by 80% through the creation of sleeve. This is accomplished by a series of endoscopically placed stitches through the stomach wall.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Intervention
Description: Standard low-calorie diet plan and moderate intensity life-style intervention of 150 minutes of aerobic exercise per week for 12 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: Standard low-calorie diet plan and moderate intensity life-style intervention of 150 minutes of aerobic exercise per week for 12 months.
Study: NCT00230763

Intervention type: PROCEDURE
Group type: OTHER
Intervention: IOP
Description: D0, D30 and D84
Study: NCT03406975

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: Standard low-calorie diet plan and moderate intensity life-style intervention of 150 minutes of aerobic exercise per week for 12 months.
Study: NCT00230763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LATANOPROST 0.005% / TIMOLOL 0.5% FIXED COMBINATION
Description: in the evening during 84 days

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Visual acuity
Description: D0 and D84
Study: NCT01108055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib (GW786034)
Description: Cycle of 28 days. Pazopanib: 800mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Cycle of 28 days Paclitaxel: 80mg/m2 days 1,8 and 15
Study: NCT01450540

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: REMstar Auto A-Flex
Description: Standard CPAP

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: modified REMstar Auto A-Flex with AGPAP
Description: Modified device -Software upgrade to GP 12
Study: NCT02354001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raloxifene hydrochloride
Description: 120mg daily- 1 capsule for 12 week trial

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule daily for 12 week trial - lactose
Study: NCT00451087

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: leg press training
Description: quadriceps muscle strengthening. 30min/ 3times/ week

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: isokinetic training
Description: quadriceps muscle training. 30 min/ 3 times/ week
Study: NCT01115712

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (to match pioglitazone 30 mg) once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Pioglitazone
Description: Pioglitazone 30 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Hyperinsulinemic Euglycemic Clamp
Description: Infusion of Glucose (20% dextrose) to achieve a glucose concentration of 90mg/dL; Infusion of Insulin at a rate of 10 mU/m2/minute from 0 to 180 minutes and at a rate of 40 mU/m2/minute from 180 to 360 minutes; Saline infusion at 60 minutes before the insulin and glucose infusions to keep the antecubital vein open.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Hyperinsulinemic Euglycemic Clamp
Description: Infusion of Glucose (20% dextrose) to achieve a glucose concentration of 90mg/dL; Infusion of Insulin at a rate of 10 mU/m2/minute from 0 to 180 minutes and at a rate of 40 mU/m2/minute from 180 to 360 minutes; Saline infusion at 60 minutes before the insulin and glucose infusions to keep the antecubital vein open.
Study: NCT04995783

Intervention type: DIAGNOSTIC_TEST
Intervention: Coral FRS test
Description: A novel clinical test to predict autoimmune medication response

Intervention type: DIAGNOSTIC_TEST
Intervention: Coral FRS test
Description: A novel clinical test to predict autoimmune medication response

Intervention type: DIAGNOSTIC_TEST
Intervention: Coral FRS test
Description: A novel clinical test to predict autoimmune medication response

Intervention type: DIAGNOSTIC_TEST
Intervention: Coral FRS test
Description: A novel clinical test to predict autoimmune medication response
Study: NCT03370263

Intervention type: DRUG
Intervention: Benlysta
Description: Benlysta will be administered intravenously or subcutaneously.

Intervention type: DRUG
Intervention: Benlysta
Description: Benlysta will be administered intravenously or subcutaneously.
Study: NCT01701063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: 100- and 250-mg chewable tablets or 375-mg film-coated tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b
Description: 50 μg/0.5 mL, 80 μg/0.5 mL, 120 μg/0.5 mL, or 150 μg/0.5 mL for subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 200-mg capsules or 40-mg/mL solution for oral administration
Study: NCT03251807

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Twin-block
Description: Functional treatment will be achieved using the Twinblock appliance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Twin-block
Description: Functional treatment will be achieved using the Twinblock appliance

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LIPUS (Low-intensity pulsed ultrasound)
Description: Functional treatment will be combined with LIPUS (Low-intensity pulsed ultrasound )
Study: NCT01839344

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quercetin
Description: Quercetin 250 mg capsules; oral single dose of 2000 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose
Description: Acarbose 100 mg tablet; oral single dose of 100 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: An oral single dose of a solid, colored empty capsule.
Study: NCT04020952

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: st.st 0.019×0.025 wire
Description: rectangular stainless steel wire that will be used during canine retraction after first premolars extraction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: st.st 0.016×0.022 wire
Description: rectangular stainless steel wire that will be used during canine retraction after first premolars extraction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: st.st 0.017×0.025 wire
Description: rectangular stainless steel wire that will be used during canine retraction after first premolars extraction
Study: NCT03151876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: 30 mg oral twice weekly for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: 6 mg/m2 intravenously daily for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 2500 mg/m2 intravenously twice weekly for 1 week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 3.2 mg/kg intravenously daily for 4 days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation
Description: autologous hematopoietic stem cells infusion after ChiCGB chemotherapy
Study: NCT01422291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: 1 gr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine
Description: 0.1mg/kg intravenous in 100 ml serum physiologic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexketoprofen
Description: 50 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamole
Description: 1 gr
Study: NCT04509453

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: McGRATH laryngoscopy
Description: Patients who underwent general anesthesia with LMA insertion by using McGRATH video layngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: McGRATH laryngoscopy
Description: Patients who underwent general anesthesia with LMA insertion by using McGRATH video layngoscopy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh laryngoscopy
Description: Patients who underwent general anesthesia with LMA insertion by using classic Macintosh video layngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscopy
Description: Patients who underwent general anesthesia with LMA insertion by using classic Macintosh video layngoscopy
Study: NCT04999501

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prolonged resistance-type exercise training
Description: All volunteers will be subjected to 12 weeks of whole-body resistance-type exercise training (3x/wk).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prolonged resistance-type exercise training
Description: All volunteers will be subjected to 12 weeks of whole-body resistance-type exercise training (3x/wk).
Study: NCT03389672

Intervention type: PROCEDURE
Intervention: spinal anesthesia
Description: For conventional spinal anesthesia, injection site was 1 cm lateral and 1 cm caudal to the spinous process, and the needle was directed cephalad and medially to the epidural-subarachnoid space by the operator. For modified method, we reduced the distance from 1cm to 0.5cm in each directions.

Intervention type: PROCEDURE
Intervention: epidural anesthesia
Description: For conventional epidural anesthesia, injection site was 1 cm lateral and 1 cm caudal to the spinous process, and the needle was directed cephalad and medially to the epidural-subarachnoid space by the operator. For modified method, we reduced the distance from 1cm to 0.5cm in each directions.

Intervention type: PROCEDURE
Intervention: combined spinal-epidural anesthesia
Description: For conventional combined spinal-epidural anesthesia, injection site was 1 cm lateral and 1 cm caudal to the spinous process, and the needle was directed cephalad and medially to the epidural-subarachnoid space by the operator. For modified method, we reduced the distance from 1cm to 0.5cm in each directions.
Study: NCT03504033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon
Description: inhalation to maintain anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: inhalation to maintain anesthesia
Study: NCT02426866

Intervention type: DRUG
Intervention: Efavirenz
Study: NCT04334941

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Given PO
Study: NCT02828033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilonacept
Description: All patients will receive rilonacept with an initial loading dose of 320 mg delivered as two, 2-mL, subcutaneous injections of 160 mg each given on the same day at two different sites. The initial dose will be administered at the study site by study personnel. Dosing will then be a once-weekly injection of 160 mg administered as a single, 2-mL, subcutaneous injection by the patient at home. Patients will be dosed for 24 weeks.
Study: NCT00809250

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-K562/leukemia cell vaccine
Description: Cultured cell line genetically changed to secrete GM-CSF mixed with irradiated leukemia cells obtained from the participant. A total of 6 vaccine will be given. Vaccines 1-3 will be given once a week. Vaccines 4-6 will be given every other week.
Study: NCT04489641

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological treatment
Description: Psychological treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medication
Description: Pharmacological intervention
Study: NCT01704859

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 placebo
Description: Vitamin D placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3 placebo
Description: Vitamin D placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil placebo
Description: Fish oil placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fish oil placebo
Description: Fish oil placebo
Study: NCT01704859

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omega-3 fatty acids (fish oil)
Description: Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omega-3 fatty acids (fish oil)
Description: Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 (cholecalciferol), 2000 IU per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 (cholecalciferol), 2000 IU per day.
Study: NCT04537897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 474121
Description: BI474121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 474121
Description: BI474121
Study: NCT03554239

Intervention type: GENETIC
Group type: OTHER
Intervention: genotyping
Description: Blood sample
Study: NCT01301326

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: subthreshold and threshold laser treatment
Description: subthreshold laser treatment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Threshold laser treatment
Description: threshold laser treatment
Study: NCT00968344

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine
Description: 3-4g Leucine added to daily meals

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Alanine
Description: Powered amino acid
Study: NCT04820192

Intervention type: OTHER
Intervention: Craniosacral Therapy
Description: The Upledger method of applying both specific and non-specific manual therapy of gentle, sustained, non-invasive stretch to soft tissues of fascia, meninges and osseous attachments. Fluid exchange is also believed to be a resulting result of CST. Treatment is applied to myofascial and osseous sites over the entire body, tending to specific and unique constellation of tissue restrictions and osseous compressions of soft tissue.

Intervention type: OTHER
Intervention: Craniosacral Therapy
Description: The Upledger method of applying both specific and non-specific manual therapy of gentle, sustained, non-invasive stretch to soft tissues of fascia, meninges and osseous attachments. Fluid exchange is also believed to be a resulting result of CST. Treatment is applied to myofascial and osseous sites over the entire body, tending to specific and unique constellation of tissue restrictions and osseous compressions of soft tissue.

Intervention type: OTHER
Intervention: Craniosacral Therapy
Description: The Upledger method of applying both specific and non-specific manual therapy of gentle, sustained, non-invasive stretch to soft tissues of fascia, meninges and osseous attachments. Fluid exchange is also believed to be a resulting result of CST. Treatment is applied to myofascial and osseous sites over the entire body, tending to specific and unique constellation of tissue restrictions and osseous compressions of soft tissue.
Study: NCT02035384

Intervention type: DRUG
Intervention: turoctocog alfa
Description: Patients will be treated with commercially available turoctocog alfa as prescribed by the treating physician in clinical daily practice and preferably according to the label for turoctocog alfa in the respective countries.